Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis

被引:21
|
作者
Qiu, Shiyuan [1 ,3 ]
Zhang, Hengci [2 ]
Yu, Sijie [3 ]
Yang, Qin [3 ]
Zhang, Gaofu [3 ]
Yang, Haiping [3 ]
Li, Qiu [3 ]
Wang, Mo [3 ]
机构
[1] Chongqing You You Baobei Womens & Childrens Hosp, Pediat Internal Med Dept, Chongqing, Peoples R China
[2] Guizhou Med Univ, Guiyang, Peoples R China
[3] Chongqing Med Univ, Dept Nephrol,Minist Educ,Key Lab Child Dev & Diso, Natl Clin Res Ctr Child Hlth & Disorders,China In, Childrens Hosp,Chongqing Key Lab Pediat, Chongqing, Peoples R China
关键词
Systemic lupus erythematosus; Lupus nephritis; Children; Prognosis; DISEASE-ACTIVITY STATE; ERYTHEMATOSUS; SLE; CLASSIFICATION; VALIDATION; REMISSION; EFFICACY; CRITERIA; CHILDREN; SAFETY;
D O I
10.1007/s00467-021-05164-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Pediatric lupus nephritis (pLN) is one of the most refractory secondary kidney diseases in childhood. The treat-to-target (T2T) strategy has become the standard treatment for systemic lupus erythematosus (SLE). This study reviewed clinical features, overall remission status, and factors affecting prognosis, to guide pLN management according to T2T strategy. Methods This single-center retrospective study studied 220 children diagnosed with LN from January 2012 to December 2018, with > 6-month follow-up data on 173 and complete data on 137 patients. Primary outcome was treatment failure (deterioration or no response) at the latest follow-up. Results The most common pLN manifestation was proteinuria (81.36%). Females presented more often with rash (P<0.001) and alopecia (P=0.026) than males. Class IV LN (33.33%) was the most common grade on kidney biopsy. Median follow-up was 27.20 months (IQR, 15.78-44.45 months). One-, 3-, and 5-year cumulative overall survival rates were 93.5%, 87.8%, and 86.5%, respectively. The 5-year cumulative kidney survival rate was 97.1%. Regarding initial therapy, efficacy of corticosteroids combined with immunosuppressive agents was significantly better than corticosteroids alone (P=0.010). Factors with P<0.05 in univariate analysis, including hypoalbuminemia, higher SCr at diagnosis, lower eGFR at diagnosis, anti-dsDNA positivity, heavy proteinuria, hypertension, nervous-system involvement, treatment non-compliance, and SLEDAI-2K score, were used for logistic regression analysis. Logistic regression analysis showed hypertension (OR=0.845, P=0.011), nervous-system involvement (OR=4.240, P=0.005), treatment non-compliance (OR=6.433, P=0.001), and lower estimated glomerular filtration rate at diagnosis (OR=1.020, P=0.021) affected prognosis. At end of follow-up, 34.31% achieved varying levels of remission, and 8.76% were in low disease activity state (LDAS). Conclusions pLN usually presented with proteinuria, and class IV LN was the dominant pathology. Hypertension, nervous-system involvement, treatment non-compliance, and lower eGFR at diagnosis were independent risk factors for poor prognosis of kidney outcomes. Compared with renal remission rate and cumulative overall survival rate, the proportion of targets achieved was not ideal, suggesting T2T strategy should be used to guide pLN management.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 50 条
  • [31] Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight
    Doria, A.
    Gatto, M.
    Iaccarino, L.
    Punzi, L.
    LUPUS, 2015, 24 (4-5) : 507 - 515
  • [32] Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
    Sanchez, Agner R. Parra
    Voskuyl, Alexandre E.
    van Vollenhoven, Ronald E.
    NATURE REVIEWS RHEUMATOLOGY, 2022, 18 (03) : 146 - 157
  • [33] ASSESSMENT OF THE IMPACT OF LUPUS NEPHRITIS ON CLINICAL, BIOLOGICAL PARAMETERS, DISEASE ACTIVITY AND MORTALITY IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
    Gacem, O.
    Labboun, L.
    Ayad, N.
    Zeroual, Z.
    Arrada, Z.
    Achir, Moussa
    Ladj, M. S.
    RHEUMATOLOGY, 2021, 60 : V2 - V2
  • [34] Egyptian recommendations for the management of systemic lupus erythematosus: a consensus, evidence-based, clinical practice guidelines for treat-to-target management
    El Miedany, Yasser
    Elhadidi, Khaled
    Mahmoud, Geilan Abdelmoneim
    Abu-Zaid, Mohammed Hassan
    Mahmoud, Atef Abdelazim
    El Gaafary, Maha
    Kamel, Nadia
    Fathi, Nihal Ahmed
    Nasser, Ahmed Abdel
    Hassan, Waleed
    Eissa, Mervat
    Sarhan, Eman
    Aboalfadl, Essam
    Mansour, Ahmed Ezzat
    Mortada, Mohamed
    Fouad, Nermeen Ahmed
    Elaraby, Ismail
    Elnemr, Rehab
    Medhat, Basma M.
    Mohamed, Sally S.
    Ibrahim, Rehab Ali
    Tabra, Samar Abd Alhamed
    Saber, Sally
    Franklin, Genny
    Mokbel, Abir
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2023, 50 (01)
  • [35] Egyptian recommendations for treating to target of lupus nephritis: an evidence-based consensus on clinical practice recommendations for the management of lupus nephritis and pregnancy
    El Miedany, Yasser
    Kamel, Nadia Salah
    Abu-Zaid, Mohammed Hassan
    El Hadidi, Khaled
    Mahmoud, Geilan Abdelmoneim
    El Gaafary, Maha
    Sarhan, Eman
    Abdel-Nasser, Ahmed
    Abualfadl, Esam M.
    Azim, Atef Abdel
    Fathi, Nihal Ahmed
    Mokbel, Abir
    Hassan, Waleed
    Eissa, Mervat
    Tabra, Samar Abd Alhamed
    Mortada, Mohamed
    Fouad, Nermeen Ahmed
    Elnemr, Rehab
    Mansour, Ahmed Ezzat
    Elaraby, Ismail
    Medhat, Basma M.
    Mohamed, Sally S.
    Abdelradi, Eman Ragab
    Ibrahim, Rehab Ali
    Saber, Sally
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2022, 49 (01)
  • [36] Egyptian recommendations for the management of systemic lupus erythematosus: a consensus, evidence-based, clinical practice guidelines for treat-to-target management
    Yasser El Miedany
    Khaled Elhadidi
    Geilan Abdelmoneim Mahmoud
    Mohammed Hassan Abu-Zaid
    Atef Abdelazim Mahmoud
    Maha El Gaafary
    Nadia Kamel
    Nihal Ahmed Fathi
    Ahmed Abdel Nasser
    Waleed Hassan
    Mervat Eissa
    Eman Sarhan
    Essam Aboalfadl
    Ahmed Ezzat Mansour
    Mohamed Mortada
    Nermeen Ahmed Fouad
    Ismail Elaraby
    Rehab Elnemr
    Basma M. Medhat
    Sally S. Mohamed
    Rehab Ali Ibrahim
    Samar abd Alhamed Tabra
    Sally Saber
    Genny Franklin
    Abir Mokbel
    Egyptian Rheumatology and Rehabilitation, 50
  • [37] Editorial: Treat-to-target in systemic lupus erythematosus: cytokine transduction pathways in SLE
    Nozaki, Yuji
    Hao, Yanjie
    Barnas, Jennifer L.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [38] Clinical-Pathological Features and Prognosis of Thrombotic Thrombocytopenic Purpura in Patients With Lupus Nephritis
    Tang Zheng
    Luo Chunlei
    Wang Zhen
    Liu Ping
    Zhang Haitao
    Hu Weixin
    Zeng Caihong
    Chen Huiping
    Liu Zhihong
    Li Leishi
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 338 (05) : 343 - 347
  • [39] CLINICAL AND LABORATORY MANIFESTATIONS AS PREDICTORS OF KIDNEY BIOPSY FINDINGS IN PATIENTS WITH LUPUS NEPHRITIS
    De Araujo Junior, Antonio Silaide
    Silva De Souza, Alexandre Wagner
    Jennings Simoes, Martin Fabio
    Kirsztajn, Gianna Mastroianni
    Cintra Sesso, Ricardo De Castro
    Sato, Emilia Inoue
    dos Reis-Neto, Edgard Tones
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 50 - 51
  • [40] Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention
    Chang, Joyce C.
    Xiao, Rui
    Burnham, Jon M.
    Weiss, Pamela F.
    PEDIATRIC RHEUMATOLOGY, 2020, 18 (01) : 88